Journal article

Radioembolization for hepatocellular carcinoma: current role and future directions - the medical oncologist's perspective

Peter Gibbs, Jeanne Tie, Lourens Bester



The incidence and impact of hepatocelluar carcinoma (HCC) continues to increase worldwide. While radical therapies such as resection, radiofrequency ablation or transplantation are potentially curative for patients with early-stage HCC, the majority of patients in routine practice present with more advanced tumors, where treatment goals are palliation and extending survival. With multiple new and promising treatment options emerging for these patients, the challenge for the medical oncologist is how best to integrate these therapies into routine clinical practice. Here we review the most recent data on the efficacy and safety of yttrium-90 radioembolization in HCC, the considerations involve..

View full abstract


Funding Acknowledgements

Portions of this review are based on discussions of an advisory board meeting convened on August 2012 in Melbourne, Australia. The authors thank the members of the advisory panel for their contribution: T Bonaventura, B Brady, A Broad, C Jackson, G Kannourakis, D Yip. The authors also thank N Swaminathan for her work on this manuscript including writing, editing and coordinating the authors' input and changes. N Swaminathan was supported by a grant from Sirtex Medical.